Evolva acquires Prosarix to strengthen in-silico capabilities

Evolva Holding SA announced the acquisition of Prosarix Ltd., a leading in silico modelling company focusing on small molecule identification, design, biosynthesis and function based in Cambridge, UK. In the past eight years, Evolva and Prosarix have worked together on multiple projects and product, the press release states. «This collaboration led both companies to conclude that a full combination and alignment of interests was the next logical step», states the press release of Evolva. Prosarix's capabilities will be integrated into all Evolva current and future projects and partnerships such as the algorithmic optimisation of gene libraries used in Evolva's proprietary combinatorial pathway technologies or the in-silico prediction of natural ingredient functions, for example how ingredients will taste based on their interaction with receptors in the tongue or nose. Prosarix's operations near Cambridge, UK, will be maintained and Prosarix employees will become Evolva employees, according to the press release. The Prosarix shareholders will receive 1.2 million Evolva shares upfront, sourced from Evolva's treasury and as such not increase the total number outstanding.